$232 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 47 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 65.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | APELLIS PHARMACEUTICALS INC | $37,838,000 | +51.0% | 554,000 | 0.0% | 16.29% | +16.7% | |
| Buy | AADI BIOSCIENCES INC | $26,132,000 | +38.7% | 1,849,402 | +20.9% | 11.25% | +7.2% | |
| BLU | Buy | BELLUS HEALTH INC | $15,191,000 | +101.5% | 1,438,500 | +76.3% | 6.54% | +55.7% |
| RLMD | Buy | RELMADA THERAPEUTICS INC | $13,535,000 | +102.2% | 365,618 | +3.7% | 5.83% | +56.3% |
| ISEE | IVERIC BIO INC | $10,111,000 | +86.5% | 563,607 | 0.0% | 4.35% | +44.1% | |
| XENE | XENON PHARMACEUTICALS INC | $9,837,000 | +18.7% | 272,500 | 0.0% | 4.24% | -8.3% | |
| BLSA | BCLS ACQUISITION CORP- CL A | $8,448,000 | +1.2% | 843,122 | 0.0% | 3.64% | -21.8% | |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $7,800,000 | +97.8% | 324,614 | +58.3% | 3.36% | +52.9% |
| CLDX | CELLDEX THERAPEUTICS INC | $7,511,000 | +4.3% | 267,195 | 0.0% | 3.23% | -19.4% | |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $7,440,000 | +174.7% | 362,735 | +55.0% | 3.20% | +112.3% |
| RLMD | New | RELMADA THERAPEUTICS INCput | $7,404,000 | – | 200,000 | +100.0% | 3.19% | – |
| KURA | KURA ONCOLOGY INC. COMMON STOCK | $7,329,000 | -25.5% | 536,500 | 0.0% | 3.16% | -42.4% | |
| MRTX | Buy | MIRATI THERAPEUTICS | $7,319,000 | +15.4% | 104,800 | +10.9% | 3.15% | -10.8% |
| Buy | VENTYX BIOSCIENCES INC | $6,284,000 | +321.2% | 180,000 | +47.5% | 2.71% | +225.6% | |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $5,758,000 | +88.0% | 27,500 | +111.5% | 2.48% | +45.4% |
| JYAC | JIYA ACQUISITION CORP -CL A | $5,608,000 | +1.0% | 562,500 | 0.0% | 2.42% | -21.9% | |
| MIST | Buy | MILESTONE PHARMACEUTICALS IN | $5,487,000 | +95.1% | 597,026 | +30.6% | 2.36% | +50.8% |
| SRPT | New | SAREPTA TEHRAPEUTICS INC | $4,587,000 | – | 41,500 | +100.0% | 1.98% | – |
| BCAB | New | BIOATLA INC | $4,004,000 | – | 520,000 | +100.0% | 1.72% | – |
| GOSS | Buy | GOSSAMER BIO INC | $3,408,000 | +1171.6% | 284,500 | +789.1% | 1.47% | +885.2% |
| FOLD | New | AMICUS THERAPEUTICS INC | $3,028,000 | – | 290,000 | +100.0% | 1.30% | – |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS INC | $2,892,000 | +32.7% | 87,500 | +41.3% | 1.24% | +2.6% |
| GHRS | GH RESEARCH PLCordinary shares | $2,827,000 | +16.4% | 243,250 | 0.0% | 1.22% | -10.1% | |
| ACRS | Sell | ACLARIS THERAPEU | $2,532,000 | -5.9% | 160,835 | -16.6% | 1.09% | -27.3% |
| EYPT | EYEPOINT PHARMACEUTICALS INC | $2,400,000 | +0.5% | 303,396 | 0.0% | 1.03% | -22.3% | |
| TERN | New | TERNS PHARMACEUTICALS INC | $2,066,000 | – | 350,702 | +100.0% | 0.89% | – |
| PCVX | New | VAXCYTE INC | $2,040,000 | – | 85,000 | +100.0% | 0.88% | – |
| PMVP | Buy | PMV PHARMACEUTICALS INC | $1,839,000 | -15.4% | 154,500 | +1.3% | 0.79% | -34.6% |
| FULC | Buy | FULCRUM THERAPEUTICS INC | $1,780,000 | +81.6% | 220,000 | +10.0% | 0.77% | +40.5% |
| ALT | New | ALTIMMUNE INC | $1,596,000 | – | 125,000 | +100.0% | 0.69% | – |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $1,472,000 | -13.6% | 153,639 | -0.5% | 0.63% | -33.2% |
| Buy | PYXIS ONCOLOGY INC | $1,318,000 | -14.1% | 669,158 | +3.7% | 0.57% | -33.6% | |
| MRUS | Sell | MERUS BV | $1,182,000 | -66.1% | 59,000 | -61.7% | 0.51% | -73.8% |
| ALLK | New | ALLAKOS INC | $1,178,000 | – | 192,500 | +100.0% | 0.51% | – |
| RZLT | Sell | REZOLUTE INC | $1,148,000 | -44.9% | 419,145 | -35.0% | 0.49% | -57.5% |
| IMGN | New | IMMUNOGEN INC | $669,000 | – | 140,000 | +100.0% | 0.29% | – |
| HZNP | Sell | HORIZON THERAPEUTICS PLC | $248,000 | -91.3% | 4,000 | -88.9% | 0.11% | -93.3% |
| ESPR | New | ESPERION THERAPEUTIC | $201,000 | – | 30,000 | +100.0% | 0.09% | – |
| IDYA | New | IDEAYA BIOSCIENCES INC | $149,000 | – | 10,000 | +100.0% | 0.06% | – |
| SWTX | SPRINGWORKS THERAPEUTICS INC | $143,000 | +16.3% | 5,000 | 0.0% | 0.06% | -10.1% | |
| New | DICE THERAPEUTICS INC | $136,000 | – | 6,700 | +100.0% | 0.06% | – | |
| ZNTL | New | ZENTALIS PHARMACEUTICALS INC | $108,000 | – | 5,000 | +100.0% | 0.05% | – |
| NGM | New | NGM BIOPHARMACEUTICALS INC | $98,000 | – | 7,500 | +100.0% | 0.04% | – |
| KNTE | New | KINNATE BIOPHARMA INC | $60,000 | – | 5,000 | +100.0% | 0.03% | – |
| TRVI | Buy | TREVI THERAPEUTICS INC | $56,000 | -42.9% | 36,302 | +3.7% | 0.02% | -56.4% |
| NUVBWS | NUVATION BIO INC*w exp 07/07/2027 | $15,000 | -40.0% | 90,832 | 0.0% | 0.01% | -57.1% | |
| BMEA | New | BIOMEA FUSION INC | $10,000 | – | 1,000 | +100.0% | 0.00% | – |
| OCUL | Exit | OCULAR THERAPEUTIX INC | $0 | – | -13,171 | -100.0% | -0.03% | – |
| VSTM | Exit | VERASTEM INC | $0 | – | -200,000 | -100.0% | -0.13% | – |
| Exit | ATHIRA PHARMA INCcall | $0 | – | -100,000 | -100.0% | -0.19% | – | |
| Exit | AC IMMUNE SAcall | $0 | – | -100,000 | -100.0% | -0.20% | – | |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -71,500 | -100.0% | -0.56% | – |
| ITOS | Exit | ITEOS THERAPEUTICS INC | $0 | – | -62,000 | -100.0% | -0.71% | – |
| ENTA | Exit | ENANTA PHARMACEUTICALS INC | $0 | – | -27,500 | -100.0% | -0.72% | – |
| DTIL | Exit | PRECISION BIOSCIENCES INC | $0 | – | -2,050,359 | -100.0% | -1.83% | – |
| HSAQ | Exit | HEALTH SCIENCES ACQUISITIONS | $0 | – | -392,500 | -100.0% | -2.18% | – |
| RCUS | Exit | ARCUS BIOSCIENCES INC | $0 | – | -167,500 | -100.0% | -2.36% | – |
| Exit | ROCHE GS | $0 | – | -16,000 | -100.0% | -2.97% | – | |
| VTGN | Exit | VISTAGEN THERAPEUTICS INC | $0 | – | -11,361,451 | -100.0% | -5.57% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.